Ozempic Was the Amuse-Bouche

GLP-1 normalized injectable health optimization for 25 million Americans. The gray market proved peptide demand at scale. The infrastructure is forming and the category is igniting.

“I never saved anything for the swim back.” — Vincent Freeman, Gattaca (1997)

I lost 40 pounds on Ozempic. I have written about this publicly. The reactions were predictable: admiration from some, skepticism from others, and strong opinions from people who had never spent five minutes thinking about peptide biology.

What I did not write about was what came next.

The GLP-1 results were remarkable. My cardiologist nearly fell out of his chair looking at my blood work. But the experience taught me something bigger than weight loss. Once you cross the injectable barrier and watch biology respond to molecular intervention in real time, your relationship with health changes. You stop thinking about health as maintenance and start thinking about it as design.

That shift is not personal. It is cultural. And it is moving faster than almost anyone in consumer investing has priced in.

The number that matters is 25 million. That is roughly how many Americans now inject semaglutide or tirzepatide regularly. Weekly. Self-administered. At home. Five years ago the idea of a mass consumer market built around injectable therapeutics would have sounded absurd. Today it is a line item in CVS’s quarterly earnings. The psychological barrier to self-injection collapsed quietly, then all at once, and it rewrote the assumptions about what consumers will and will not do in pursuit of health.

That is the setup for what comes next.

Peptides are biological signaling molecules that instruct the body to perform specific functions: repair tissue, regulate inflammation, stimulate collagen production, optimize sleep, accelerate recovery. They are not drugs in the traditional pharmaceutical sense. They are a more precise conversation with the body’s own systems.

Andrew Huberman introduced them to millions. Peter Attia normalized molecular intervention as part of a serious longevity protocol. Bryan Johnson made self-experimentation aspirational. Rhode turned peptides into a beauty product with billion-dollar scale. The word moved from lab report to beauty shelf to consumer vocabulary without anyone calling a press conference.

Here is what most people watching this space have missed. The gray market did not create the peptide opportunity. It proved it.

For years, research chemical vendors sold peptides in a legal gray area, technically for research purposes, functionally for human use. Peptide Sciences, the largest of these vendors, built what was almost certainly a nine-figure business. Millions of customers. Strong repeat purchasing. Word of mouth that no marketing budget could manufacture.

Then on March 6th of this year, Peptide Sciences posted three sentences and shut it down. No raid. No indictment. They assessed the regulatory trajectory and chose to exit.

Consider what that means. A company with millions of customers decided the operating environment was deteriorating fast enough to walk away. The gray market’s biggest player removing themselves is not a signal that the category is dying. It is a signal that it is legitimizing. Those millions of customers did not stop wanting peptides. They lost their supplier.

The infrastructure to serve them is now forming. Physician networks prescribing through telehealth. Compounding pharmacies building 503A capabilities. Regulatory clarity appearing, with RFK Jr. recently signaling that 14 key peptides, including BPC-157 and TB-500, could move toward FDA recognition. The compounds that built the gray market may become legitimate therapeutics. If that happens, the category will not grow linearly.

Most people I know who started on Ozempic did not stop there. They got curious. They started asking what else was possible. I am living proof of that arc. Six months into peptides (BPC-187 & NAD+), moving to retatrutide this week, never felt better or thought more clearly about my own health. That is not a testimonial. That is a data point in a pattern playing out across an entire generation of consumers who are done being passive about their own biology.

The body is becoming programmable infrastructure. The way software became a platform in the 2000s, biology is becoming one now. The companies that show up before the consumer is confused, before every telehealth platform has a peptide tab, before the category gets noisy, will earn something that cannot be bought later at any price: trust.

The last great consumer health category was GLP-1. The next one is already here. Most people just have not noticed yet.

We have. If you are building in the peptide space, we want to talk.

Operators are standing by. brian@sugarcap.com